Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.48 |
| ▸ | HRH1 | P35367 | 6/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | PTAFR | P25105 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116710 | 0.91 | SETD7 (0.51) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL25616981 | 0.89 | PTAFR (0.43) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL2604745 | 0.86 | PTAFR (0.41) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL27300170 | 0.83 | SETD7 (0.48) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL6990036 | 0.81 | SETD7 (0.48) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL7092907 | 0.81 | SETD7 (0.56) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL5060512 | 0.80 | SETD7 (0.52) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| Alcaftadine SCHEMBL1602418 | 0.80 | SETD7 (0.52) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| Alcaftadine SCHEMBL29378093 | 0.80 | SETD7 (0.52) | SETD7CHRM2CHRM1HRH1ADRA1A | |
| SCHEMBL6990642 | 0.79 | MAPK1 (0.52) | SETD7CHRM2CHRM1HRH1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | JOHNSON & JOHNSON VISION CARE, INC. | 2021-02-04 | — | — | US | disclosed |
| US-10617695-B2 | Ophthalmic compositions containing alcaftadine | VISTAKON PHARMACEUTICALS, LLC (US) | 2020-04-14 | — | — | US | disclosed |
| US-20170065605-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | VISTAKON PHARMACEUTICALS, LLC | 2017-03-09 | — | — | US | disclosed |
| US-20170065605-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | VISTAKON PHARMACEUTICALS, LLC | 2017-03-09 | — | — | US | disclosed |
| US-9580436-B2 | Process of preparing alcaftadine | ENALTEC LABS PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-20120094978-A1 | Ocular Allergy Treatments | PARASRAMPURIA JAGDISH (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094978-A1 | Ocular Allergy Treatments | PARASRAMPURIA JAGDISH (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181594-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885CHRM2 1362/4885CHRM1 2168/4885 |
| US-20170065605-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885CHRM2 1362/4885CHRM1 2168/4885 |
| US-20210030762-A1 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | CCL11, HRH2, IL5 | SETD7 2348/4885CHRM2 1362/4885CHRM1 2168/4885 |
| US-20120094978-A1 | Ocular Allergy Treatments | HRH2, CMA1, TPSAB1 | SETD7 2609/4885CHRM2 1416/4885CHRM1 2251/4885 |
| US-10617695-B2 | Ophthalmic compositions containing alcaftadine | CCL11, PDE6H, ADRB1 | SETD7 1999/4885CHRM2 1101/4885CHRM1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.